HomeInsightsStock Comparison

Balaxi Pharmaceuticals Ltd vs Divis Laboratories Ltd Stock Comparison

Balaxi Pharmaceuticals Ltd vs Divis Laboratories Ltd Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

  • The Latest Trading Price of Balaxi Pharmaceuticals Ltd is ₹ 27.51 as of 06 May 15:30 . The P/E Ratio of Balaxi Pharmaceuticals Ltd changed from 13.8 on March 2021 to 14.1 on March 2025 . This represents a CAGR of 0.43% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Balaxi Pharmaceuticals Ltd changed from ₹ 524.5 crore on March 2021 to ₹ 352.89 crore on March 2025 . This represents a CAGR of -7.62% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 72.64 crore as compare to the Sep '25 revenue of ₹ 57.76 crore. This represent the growth of 25.76% The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The ebitda of Balaxi Pharmaceuticals Ltd for the Dec '25 is ₹ 3.19 crore as compare to the Sep '25 ebitda of ₹ 2.75 crore. This represent the growth of 16% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The net profit of Balaxi Pharmaceuticals Ltd changed from ₹ 6.48 crore to ₹ 0.31 crore over 7 quarters. This represents a CAGR of -82.40% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The Dividend Payout of Balaxi Pharmaceuticals Ltd changed from 3.41 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Balaxi Pharmaceuticals Ltd

  • Balaxi Pharmaceuticals Limited was initially incorporated in the name of 'The Anandam Rubber Company Limited' on September 28, 1942.
  • The Company changed its name from 'The Anandam Rubber Company Limited' to 'Balaxi Ventures Limited' on August 08, 2017 and further changed to Balaxi Pharmaceuticals Limited in 2021.
  • Initially, the Company was incorporated with the object of running rubber and tea plantations and owns several plantations across South India. In year 1989 the company sold its entire plantations to meet the emerging business needs and started concentrating in Investments and trading.
  • The company previously was a investment company, but the company during the financial year 2018-19 has commenced the business of International Wholesale Trading of Pharmaceuticals, Builders Hardware and FMCG Products On 15 March 2017, Balaxi Overseas Private Limited (BOPL) entered into a Share Purchase Agreement (SPA) with the erstwhile promoters of Company (i.

About Divis Laboratories Ltd

  • Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
  • The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
  • It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
  • In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
  • It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Balaxi Pharmaceuticals Ltd or Divis Laboratories Ltd?

Market cap of Balaxi Pharmaceuticals Ltd is 151 Cr while Market cap of Divis Laboratories Ltd is 178,025 Cr

What are the key factors driving the stock performance of Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd?

The stock performance of Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd?

As of May 6, 2026, the Balaxi Pharmaceuticals Ltd stock price is INR ₹27.51. On the other hand, Divis Laboratories Ltd stock price is INR ₹6706.1.

How do dividend payouts of Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Balaxi Pharmaceuticals Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions